Longevity Health Holdings, Inc. has announced an update to its merger agreement with 20/20 Biolabs, Inc. Originally disclosed on April 11, 2025, the Agreement and Plan of Merger involves Longevity Health Holdings' subsidiary, Longevity Health Biomarkers, Inc., merging with 20/20 Biolabs, which will then continue as a wholly owned subsidiary of Longevity Health Holdings. On June 24, 2025, the involved parties amended the original agreement to extend the Due Diligence Contingency Deadline to July 8, 2025. If not further extended by mutual consent, the merger agreement will automatically terminate on that date.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。